FDA to Review Intranasal Zavegepant for Migraine Treatment
The NDA submission includes data from 2 pivotal studies that evaluated zavegepant in adults with at least a 1-year history of migraine and migraine attacks.
Migraine and Headache
Atogepant Reduces Monthly Migraine Days in Chronic Migraine Trial
The PROGRESS study compared the efficacy and safety of atogepant to placebo in 778 adults with at least a 1-year history of chronic migraine.
Migraine-Diet Connection: Dietary Triggers and Interventions for Migraine Management
Lauren R. Natbony, MD, takes us on a deep dive into the association between nutrition and dietary patterns in migraine, including proposed mechanisms, and the remaining needs in patient education and research.
Erenumab vs Topiramate in Patients With Migraine: Head-to-Head Study Results
The HER-MES trial included 777 adults with episodic or chronic migraine (at least 4 migraine days/month) who were treatment-naïve, not suitable for, or had previously failed up to 3 prophylactic migraine treatments.
Understanding Chronic Migraine: From Pathophysiology to Treatment Disparities
An expert roundtable of headache specialists helps outline chronic migraine as its own entity, disparities and barriers to treatment, and a need for better research and education.
Trudhesa Nasal Spray Now Available for Acute Treatment of Migraine
Trudhesa uses proprietary technology to deliver a lower dose (0.725mg per spray) of dihydroergotamine mesylate to the upper nasal space.
FDA Clears VNS Device for Paroxysmal Hemicrania, Hemicrania Continua
Patients treated with gammaCore experienced clinically meaningful benefits.
Meloxicam/Rizatriptan Combo Under Review for Migraine Treatment
The application is supported by data from the phase 3 MOMENTUM and INTERCEPT trials.
Trudhesa Nasal Spray Approved for Acute Treatment of Migraine
The approval is supported by data from the phase 3 STOP 301 study, which evaluated the safety and tolerability of Trudhesa in 354 adults with migraine.
Study Compares Remote Electrical Neuromodulation to Migraine Meds in Adolescents
Nerivio is a wireless remote electrical neuromodulation device approved for the acute treatment of episodic or chronic migraine in patients 12 years of age and older.
- Loading...
Loading...
Loading... 
Loading...